Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: The utility of the necessity-concerns framework

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 3, 2007, Pages 334-341

  Horne, Robert ^a   Cooper, Vanessa ^b   Gellaitry, Grace ^b   Date, Heather Leake ^c   Fisher, Martin ^c  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BRIGHTON   (United Kingdom)

^c ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; HIV; Knowledge attitude practice studies; Nonadherence; Treatment beliefs; Treatment refusal

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ADVERSE OUTCOME; ARTICLE; BIVARIATE ANALYSIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONCEPTUAL FRAMEWORK; CONFIDENCE INTERVAL; DECISION MAKING; FEMALE; FOLLOW UP; HEALTH BELIEF; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK; TREATMENT WITHDRAWAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GREAT BRITAIN; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; PATIENT COMPLIANCE; QUESTIONNAIRES; TREATMENT REFUSAL;

EID: 34347326156     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31806910e3     Document Type: Article

References (55)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Sterne JAC, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366:378-384.
4. Phillips A, CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS. 2004;18:51-58.
5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
6. Maisels L, Steinberg J, Tobias C. An investigation of why eligible patients do not receive HAART. AIDS Patient Care STDS. 2001;15:185-191.
7. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756-765.
8. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
9. McNabb J, Ross JW, Abriola K, et al. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-705.
10. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417-1423.
11. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
12. Gross R, Bilker WB, Friedman HM, et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15:2109-2117.
13. Gazzard B, BHIVA Writing Committee. British HIVAssociation (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2005;6 (Suppl 2):1-61.
14. Catt S, Stygall J, Catalan J. Acceptance of zidovudine (AZT) in early HIV disease: the role of health beliefs. AIDS Care. 1995;7:229-235.
15. Ezzy EM, Bartos MR, de Visser RO, et al. Antiretroviral uptake in Australia: medical, attitudinal and cultural correlates. Int J STD AIDS. 1998;9:579-586.
16. Gold RS, Hinchy J, Bartouney CG. The reasoning behind decisions not to take up antiretroviral therapy in Australians infected with HIV. Int J STD AIDS. 2000;11:361-370.
17. Gold RS, Ridge DT."I will start treatment when I think the time is right:" HIV-positive gay men talk about their decision not to access antiretroviral therapy. AIDS Care. 2001;13:693-708.
18. Misener TR, Sowell RL. HIV-infected women's decisions to take antiretrovirals. West J Nurs Res. 1998;20:431-447.
19. Siegel K, Gorey E. HIV-infected women: barriers to AZT use. Soc Sci Med. 1997;45:15-22.
20. Siegel K, Raveis VH, Krauss BJ. Factors associated with urban gay men's treatment initiation decisions for HIV infection. AIDS Educ Prev. 1992;4:135-142.
21. Stall R, Hoff C, Coates TJ, et al. Decisions to get tested and to accept antiretroviral therapies among gay/bisexual men: implications for secondary prevention efforts. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:151-160.
22. Cooper V, Buick D, Horne R, et al. Perceptions of HAART among gay men who declined a treatment offer: preliminary results from an interview-based study. AIDS Care. 2002;14:319-328.
23. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47-58.
24. Aversa SL, Kimberlin C. Psychosocial aspects of antiretroviral medication use among HIV patients. Patient Educ Couns. 1996;29:207-219.
25. Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-133.
26. Gebo KA, Keruly J, Moore RD. Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy. J Gen Intern Med. 2003;18:104-111.
27. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2:38-45.
28. Spire B, Duran S, Souville M, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54:1481-1496.
29. Chesney M, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments. AIDS Care. 2000;12:255-266.
30. Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr. 1998;18:117-125.
31. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-395.
32. Molassiotis A, Nahas-Lopez V, Chung WY, et al. Factors associated with adherence to antiretroviral medication in HIV-infected patients. Int J STD AIDS. 2002;13:301-310.
33. Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care. 2000;12:377-386.
34. Sankar A, Luborsky M, Schuman P, et al. Adherence discourse among African-American women taking HAART. AIDS Care. 2002;14:203-218.
35. Haynes R, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev. 2005;4:CD000011.
36. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555-567.
37. Horne R. Representations of medication and treatment: advances in theory and measurement. In: Petrie K, Weinman JA, eds. Perceptions of Health and Illness. Amsterdam, The Netherlands: Harwood Academic Publishers; 1997:155-188.
38. Horne R. Treatment perceptions and self regulation. In: Cameron LD, Leventhal H, eds. The Self-Regulation of Health and Illness Behaviour. London: Routledge; 2003:138-154.
39. Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1-24.
40. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health. 2002;14:1-24.
41. Horne R, Buick D, Fisher M, et al. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS. 2004;15:38-44.
42. BHIVA Writing Committee, BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2001;2:276-313.
43. BHIVA Writing Committee, BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2003;4:1-41.
44. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
45. Walsh JC, Mandalia S, Gazzard BG. Responses to a one month self report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16:269-277.
46. Gellaitry G, Cooper V, Peters K, et al. The perceived impact of HAART on gay men's sexual relationships: an interview based study. Presented at: Conference on AIDS Impact; 2005; Cape Town.
47. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA. 2004;292:266-268.
48. McDonald K, Bartos M, Rosenthal D. Australian women living with HIV/AIDS are more sceptical than men about antiretroviral treatment. AIDS Care. 2000;13:15-26.
49. Erwin J, Peters B. Treatment issues for HIV+ Africans in London. Soc Sci Med. 1999;49:1519-1528.
50. Siegel K, Karus D, Scrimshaw EW. Racial differences in attitudes toward protease inhibitors among older HIV-infected men. AIDS Care. 2000;12:423-434.
51. Sabin CA, Smith CJ, Gumley H, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS. 2004;18:2145-2151.
52. Garber MC, Nau DP, Erickson SR, et al. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004;42:649-652.
53. Gross R, Yip B, Wood E, et al. Boosted PI are more forgiving of suboptimal adherence than non-boosted PI or NNRTI. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver.
54. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-941.
55. Mocroft A, Phillips AN, Soriano V, et al, for the EuroSIDA Study Group. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses. 2005;21:743-752.